This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (August 2012) (Learn how and when to remove this template message) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (July 2023) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Gevork Minaskanian is an American research professor in the Department of Chemistry at Virginia Commonwealth University[1] and Co-founder/Vice President of Synthetic Chemistry [2] at Aderis Pharmaceuticals who was a contributor to the development of rotigotine and Neupro (a transdermal patch that delivers rotigotine). Rotigotine is a drug developed to mimic the actions of dopamine in the brain to help cope with restless legs syndrome and the abnormal movements(dyskinesia) found in Parkinson's disease patients. This drug is an alternative to oral medications for treatment of Parkinson's disease, considered by the VCU Department of Chemistry as "an unprecedented medication for the benefit of millions of Parkinson's patient worldwide."[3] Minaskanian’s main contribution to Neupro was improving the efficiency of manufacturing rotigotine, thereby making the process commercially viable and enabling patients to afford this important medication. Dr. Minaskanian is the inventor and author of over 50 patents and publications in various fields of organic and medicinal chemistry. Some of his US patents include patents 5,470,848;[4] 4,801,586;[5] 5,234,959;[6] 5,118,676;[7] and other related research done on rotigotine and Neupro US patent 7,309,497[8] found in the United States Patent and Trademark Office linked to the penetration enhancers for transdermal delivery of systemic agents.

References

  1. ^ VCU Department of Chemistry recognizing Dr. Minaskanian as a research professor and faculty (VCU Department of Chemistry)
  2. ^ Document excerpt filed by Aderis Pharmaceuticals INC. filling Dr. Gevork Minaskanian as the Vice President of Synthetic Chemistry at Aderis (excerpt from a S-1/A SEC Filin)
  3. ^ VCU Department of Chemistry recognizing Dr. Minaskanian research work on rotigotine and Neupro as an unprecedented medication for the benefit of millions of Parkinson’s patients worldwide (VCU Department of Chemistry)
  4. ^ US Patent 5,470,848 Dr. Minaskanian's latest patents related to the subject of transdermal delivery systems from 1995 (US Patent 5,470,848)
  5. ^ Dr. Minaskanian's older US patents related to the subject of transdermal delivery systems from 1989 (US Patent 4,801,586)
  6. ^ Another US Patent that Dr. Minaskanian has related to Neupro (US Patent 5,234,959)
  7. ^ Another US Patent that Dr. Minaskanian has related to Neupro (US Patent 5,118,676)
  8. ^ US Patent 7,309,497 containing a list of some of Dr. Minaskanian's work used by Schwarz Pharma AG to do newer research (US Patent 7,309,497 7)


This article needs additional or more specific categories. Please help out by adding categories to it so that it can be listed with similar articles. (February 2022)
Categories